Psilocybin analogs, salts, compositions, and methods of use
AssigneeCybin IRL Limited
InventorsAlex Nivorozhkin, Pradip Pathare, Kenneth L. Avery
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to psilocin compounds and pharmaceutically acceptable salts, polymorphs, stereoisomers, or solvates thereof, to pharmaceutical compositions, and in some embodiments, to serotonin 5-HT2 receptor agonists and uses in the treatment of diseases associated with a 5-HT2 receptor.
Claims23
A crystalline pharmaceutically acceptable salt of a compound of Formula (I), as determined by X-ray powder diffraction, or a stereoisomer, or solvate thereof
- wherein:
- R2, R5, R6, and R7 are independently selected from the group consisting of hydrogen and deuterium,
- R8 and R9 are independently selected from the group consisting of —CH3 and —CD3,
- X1 and X2 are deuterium, and
- Y1 and Y2 are independently selected from the group consisting of hydrogen and deuterium.
A crystalline compound of Formula (I), or a stereoisomer or a solvate thereof
- wherein:
- R2, R5, R6, and R7 are independently selected from the group consisting of hydrogen and deuterium,
- R8 and R9 are independently selected from the group consisting of —CH3 and —CD3,
- X1 and X2 are deuterium, and
- Y1 and Y2 are independently selected from the group consisting of hydrogen and deuterium.
A citrate salt of a compound of Formula (I), as determined by X-ray powder diffraction, or a stereoisomer, or solvate thereof
- wherein:
- R2, R5, R6, and R7 are independently selected from the group consisting of hydrogen or deuterium,
- R8 and R9 are independently selected from the group consisting of —CH3 and —CD3,
- X1 and X2 are deuterium, and
- Y1 and Y2 are independently selected from the group consisting of hydrogen and deuterium.
Dependencies are inferred from the claim text.